Clinical Trial Update: Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for 4SCAR-276 targeting CD276 (B7-H3) in solid tumors across Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• 4SCAR-276

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN